Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C21H23ClN2O4 |
Molecular Weight | 402.871 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@H](CC1=CNC2=C1C=CC=C2OCC(O)=O)NC[C@H](O)C3=CC=CC(Cl)=C3
InChI
InChIKey=FHEYFIGWYQJVDR-ACJLOTCBSA-N
InChI=1S/C21H23ClN2O4/c1-13(23-11-18(25)14-4-2-5-16(22)9-14)8-15-10-24-21-17(15)6-3-7-19(21)28-12-20(26)27/h2-7,9-10,13,18,23-25H,8,11-12H2,1H3,(H,26,27)/t13-,18+/m1/s1
Molecular Formula | C21H23ClN2O4 |
Molecular Weight | 402.871 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Rafabegron (also known as TAK-677 ) is an indole derivative patented by Dainippon Pharmaceutical Co., Ltd., as antidiabetics and antiobesity agent. Rafabegron asts as beta3-adrenergic agonist. In preclinical studies Rafabegron reduced the total weight of white adipose tissues by reducing the size of the adipocytes, an effect associated with the normalization of tumor necrosis factor-alpha and leptin expression levels in micce. The levels of uncoupling protein (UCP)-1 mRNA in brown adipose tissue were increased threefold. Rafabegron caused a marked increase (20- to 80-fold) in the expression of UCP-1 in white adipose tissues. In clinical trials. Rafabegron has no effect on 24-h respiratory quotient or fat oxidation but does slightly increase 24-h energy expenditure at the highest dose. The acute studies showed large interindividual variability in plasma concentrations of Rafabegron indicating some possible problems with bioavailability and therefore efficacy. Based on these data further development was discontinued.
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17118998
0.1 mg or 0.5 mg twice daily
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:15:26 GMT 2025
by
admin
on
Mon Mar 31 18:15:26 GMT 2025
|
Record UNII |
LN3E1Q0SU2
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C48149
Created by
admin on Mon Mar 31 18:15:26 GMT 2025 , Edited by admin on Mon Mar 31 18:15:26 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID80179162
Created by
admin on Mon Mar 31 18:15:26 GMT 2025 , Edited by admin on Mon Mar 31 18:15:26 GMT 2025
|
PRIMARY | |||
|
5493324
Created by
admin on Mon Mar 31 18:15:26 GMT 2025 , Edited by admin on Mon Mar 31 18:15:26 GMT 2025
|
PRIMARY | |||
|
300000034369
Created by
admin on Mon Mar 31 18:15:26 GMT 2025 , Edited by admin on Mon Mar 31 18:15:26 GMT 2025
|
PRIMARY | |||
|
8318
Created by
admin on Mon Mar 31 18:15:26 GMT 2025 , Edited by admin on Mon Mar 31 18:15:26 GMT 2025
|
PRIMARY | |||
|
CHEMBL279260
Created by
admin on Mon Mar 31 18:15:26 GMT 2025 , Edited by admin on Mon Mar 31 18:15:26 GMT 2025
|
PRIMARY | |||
|
C96753
Created by
admin on Mon Mar 31 18:15:26 GMT 2025 , Edited by admin on Mon Mar 31 18:15:26 GMT 2025
|
PRIMARY | |||
|
LN3E1Q0SU2
Created by
admin on Mon Mar 31 18:15:26 GMT 2025 , Edited by admin on Mon Mar 31 18:15:26 GMT 2025
|
PRIMARY | |||
|
244081-42-3
Created by
admin on Mon Mar 31 18:15:26 GMT 2025 , Edited by admin on Mon Mar 31 18:15:26 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> AGONIST |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|